Peter B. Berger, MD

Original Contribution

Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel

09/15/2015

Mian Muhammad Ali Akram , MD;

Ibrahim Ismail-Sayed , MD;

Yvette M. Henry , PhD;

Melissa A. Troup ;

Peter B. Berger , MD;

Eddy Mizrahi , MD;

Ramya Smitha Suryadevara , MD;

Kulpreet Barn , MD;

Gouthami Boga , MD;

The authors present a retrospective analysis to determine the safety and efficacy of administering prasugrel at the time of percutaneous coronary intervention (PCI), and switching to clopidogrel, without reloading.

The authors present a...

09/15/2015

Journal of Invasive Cardiology

Original Contribution

Timing and Correlates of Very Early Major Adverse Clinical Events Following Percutaneous Coronary Intervention

08/01/2008

Peter B. Berger , MD;

James L. Orford , MBChB, MPH, MD;

Joseph Jozic , MD;

Amy Hsu , MD, MS;

Steven R. Steinhubl , MD;

Eric J. Topol , MD;

The timing of, and risk factors for, very early (< 24 hours) major adverse clinical events (death, myocardial infarction [MI], urgent target vessel revascularization [uTVR], and major bleeding) following percutaneous coronary intervention...

The timing of, and risk factors...

08/01/2008

Journal of Invasive Cardiology

Safety and Efficacy of Cutting Balloon Angioplasty: The Mayo Clinic Experience

08/01/2008

Kirk N. Garratt , MD, MSc;

Peter B. Berger , MD;

David R. Holmes Jr., MD;

Panayotis Fasseas , MD;

Ali E. Denktas , MD;

James L. Orford , MBChB, MPH, MD;

LaVon Hammes ;

Gregory W. Barsness , MD;

There have been rapid improvements in percutaneous coronary intervention since its introduction. However, complex lesions unsuitable for routine angioplasty continue to pose a significant problem. A number of alternative devices have been...

There have been rapid...

08/01/2008

Journal of Invasive Cardiology

Hurry, It’s a STEMI! But How Quick is Too Quick for Safety?

07/31/2013

David R. Holmes Jr., MD;

E. Magnus Ohman , MD;

Barry F. Uretsky , MD;

Peter B. Berger , MD;

Eric Bates ;

Gregg W. Stone , MD, FACC, FSCAI;

Robert J. Applegate , MD;

Sunil V. Rao , MD, FACC, FSCAI;

Ted Feldman , MD, FSCAI, FACC, FESC;

Morton J. Kern , MD, MSCAI, FACC, FAHA;

Christopher J. White , DO, MD;

I asked my expert cath lab colleagues to weigh in on this issue with 3 quick answers on whether forced reduction of D2B time is 1) beneficial for the patient or 2) the hospital or 3) the interventionalist, and if you have time, a short...

I asked my expert cath lab...

07/31/2013

Cath Lab Digest

Commentary

Diabetes Mellitus and Preferred Method of Coronary Revascularization ‚Äî The Debate Continues

08/01/2008

James L. Orford , MBChB, MPH, MD;

Peter B. Berger , MD;

Diabetes mellitus is a public health problem of increasing importance in both the developed and developing worlds.1 The prevalence of obesity, the metabolic syndrome, and in particular diabetes, continues to increase; the impact on present...

Diabetes mellitus is a public...

08/01/2008

Journal of Invasive Cardiology

Case Report

Alveolar Hemorrhage Associated with Periprocedural Eptifibatide Administration

08/01/2008

Peter B. Berger , MD;

David R. Holmes Jr., MD;

James L. Orford , MBChB, MPH, MD;

Panayotis Fasseas , MD;

Eptifibatide, a cyclic heptapeptide inhibitor of the platelet membrane glycoprotein (GP) IIb/IIIa receptor, reduces the incidence of ischemic complications when administered at the time of percutaneous coronary intervention (PC I).1 Major...

Eptifibatide, a cyclic...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention Reduces Ischemic Events without Affecting the Need

08/01/2008

Sorin J. Brener , MD;

Steven R. Steinhubl , MD;

Eric J. Topol , MD;

Danielle M. Brennan , MS;

Peter B. Berger , MD;

When clopidogrel is added to background aspirin therapy, it reduces the composite of cardiovascular death, myocardial infarction (MI) or stroke in patients with acute coronary syndromes (ACS)1 or percutaneous revascularization.2 The most...

When clopidogrel is added to...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Feasibility and Safety of Ad Hoc Percutaneous Coronary Intervention in the Modern Era

05/04/2009

James C. Blankenship , MD;

Kimberly A. Skelding , MD, FACC, FAHA, FSCAI;

Peter B. Berger , MD;

Christopher W. Good , DO;

G. Craig Wood ;

Thomas D. Scott , DO;

ABSTRACT: Background. The frequency of ad hoc percutaneous coronary intervention (PCI) varies among institutions and regions of the country. It is unclear what factors limit use of the ad hoc strategy. Objective. To define factors which limit...

ABSTRACT: Background. The...

05/04/2009

Journal of Invasive Cardiology

Original Contribution

Outcomes of Unselected Recipients of Sirolimus-Eluting Stents: The Cypher¬Æ Stent U.S. Post-Marketing Surveillance Registry

02/02/2010

Peter C. Block , MD;

Hiram G. Bezerra , MD, PhD;

Emerson C. Perin , MD, PhD;

Marco A. Costa , MD, PhD;

Gary L. Schaer , MD, FACC, FSCAI;

Stanley Katz , MD, FACC;

Peter B. Berger , MD;

Eric J. Dippel , MD;

Stephen R. Ramee , MD;

Sidney A. Cohen , MD, PhD;

Mirle A. Kellett , MD;

Suzanne Britto , RN;

ABSTRACT: Objective. To examine the 1-year safety and clinical outcomes associated with the post-marketing early unselected use of sirolimus-eluting stents (SES) in the United States. Background. The safety and effectiveness of SES has been...

ABSTRACT: Objective. To examine...

02/02/2010

Journal of Invasive Cardiology

Original Contribution

Recurrent Cardiovascular Events with Paclitaxel-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Lesions: Insights from the SOS (Stenting of Saphenous Vein Grafts) Trial

05/26/2011

Tesfaldet T. Michael , MD, MPH;

Donald Haagen , RCIS, MD;

Tayo Addo , MD;

Aristotelis C. Papayannis , MD;

Abdul-Rahman Abdel-Karim , MD;

Bilal Saeed , MD;

Panagiotis Karyofillis , MD;

Biswajit Kar , MD;

Peter B. Berger , MD;

Christopher Lichtenwalter , MD;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

Owen Obel , MD;

Subhash Banerjee , MD, FSCAI;

Joseph K. Bissett , MD;

Rajesh Sachdeva , MD;

Vassilios V. Voudris , MD, PhD;

Michele Roesle , RN, BSN, MD;

James Rossen , MD;

Bavana V. Rangan , BDS, MPH, MD;

Panayotis Fasseas , MD;

James A. de Lemos , MD;

ABSTRACT: The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions,...

ABSTRACT: The Stenting of...

05/26/2011

Journal of Invasive Cardiology